Aflibercept after failed intravitreal bevacizumab may be effective in radiation retinopathy

Results of a pilot study suggest that patients with radiation retinopathy may respond to intravitreal aflibercept after failed monthly bevacizumab.

Researchers evaluated visual acuity (VA) and central foveal thickness (CFT) responses in 30 patients with radiation retinopathy after switching to aflibercept.

At 1 month, 3 months, and 6 months following the switch to aflibercept there was a statistically significant reduction in CFT (476 μm ± 170 to 386 μm ± 139 at 6 months) and improvements in VA (476 μm ± 170 to 386 μm ± 139 at 6 months).

There was a CFT improvement of ≥100 μm in 46% of patients and a VA of ≥1 line improvement in 23% of patients after 6 months of treatment with aflibercept.

Reference
Srivastava O, Weis E. Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept. Ocul Oncol Pathol. 2023;8(4-6):230-235. doi: 10.1159/000526548. Epub 2022 Sep 1. PMID: 36925730; PMCID: PMC10013499.